Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung

[1]  Z. Xiang,et al.  Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[3]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  James M. Wilson,et al.  Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. , 1994, Human gene therapy.

[5]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[6]  James M. Wilson,et al.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.

[7]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Wilson,et al.  In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. , 1994, The Journal of biological chemistry.

[9]  B. Trapnell,et al.  Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.

[10]  M. Kay,et al.  In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Finkelman,et al.  Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. , 1994, Journal of immunology.

[12]  W. Paul,et al.  Lymphocyte responses and cytokines , 1994, Cell.

[13]  J. Wilson,et al.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. , 1993, Human gene therapy.

[14]  B. Trapnell,et al.  Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice , 1993, Nature Genetics.

[15]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[16]  R. Rerko,et al.  Recombinant interleukin 12 cures mice infected with Leishmania major , 1993, The Journal of experimental medicine.

[17]  P. Scott.  IL-12: initiation cytokine for cell-mediated immunity. , 1993, Science.

[18]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[19]  Giorgio,et al.  Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells , 1992, The Journal of experimental medicine.

[20]  J. Mandel,et al.  Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Perricaudet,et al.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.